
JPMorgan raised the firm’s price target on Definium Therapeutics (DFTX) to $85 from $84 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| DFTX | Definium Therapeutics | 29.12 | 18.19 | 166.42% |
| Name | Price | % Change | |
|---|---|---|---|
| $29.12 | +166.42% |

JPMorgan raised the firm’s price target on Definium Therapeutics (DFTX) to $85 from $84 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source

Definium Therapeutics, Inc. (($DFTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Definium Therapeutics delivered a strongly positive earnings call, supported by three

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a NDA submission and a psilocybin shipment. EARNINGS: On Monday, Definium

“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically

RBC Capital raised the firm’s price target on Definium Therapeutics (DFTX) to $70 from $66 and keeps an Outperform rating on the shares after its Q3 results. Regulatory updates are

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on DFTX stock, giving a Buy rating today. Tessa Romero’s rating is based on a combination of Definium Therapeutics’ clinical

Definium Therapeutics ( ($DFTX) ) has provided an update. Definium reported positive topline Phase 3 results for DT120 ODT in the Voyage and Panorama GAD studies. Both trials met primary

Definium Therapeutics ( ($DFTX) ) has provided an update. Definium Therapeutics announced plans to host a webcast at 4:30 p.m. EST on November 9, 2026, to report financial results for

The latest announcement is out from Definium Therapeutics ( ($DFTX) ). Definium Therapeutics is a late-stage clinical biopharmaceutical company developing therapeutics intended to address underlying causes of psychiatric and neurological

Definium Therapeutics ( ($DFTX) ) has issued an update. Definium Therapeutics, a late-stage clinical biopharmaceutical company developing therapeutics for psychiatric and neurological disorders, announced four poster presentations on DT120 ODT
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Assigned | Nov 17, 2026 | ||||
| buy | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 11, 2027TBA | $4.02B | $-0.50 | $0.00 | -0.19 | -9.65 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.